查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乳癌液體活檢市場：成長、未來展望和競爭分析（2024-2032 年）
市場調查報告書
商品編碼
1642607

乳癌液體活檢市場：成長、未來展望和競爭分析（2024-2032 年）

Breast Cancer Liquid Biopsy Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
出版日期: | 出版商: Acute Market Reports | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

預計 2024-2032 年預測期內乳癌液體活檢市場將以 22.7% 的複合年增長率成長。乳癌液體活檢市場是一個快速發展的領域，利用非侵入性液體活檢透過血液樣本檢測和監測乳癌。該方法比傳統的組織活檢有了顯著的進步，可以即時洞察腫瘤動態並制定個人化的治療策略。該技術具有徹底改變癌症檢測和管理的潛力，並處於腫瘤學研究和臨床應用的前沿。

促進因素

基因組技術的進展

基因組定序和分析技術的進步是推動乳癌液體活檢市場發展的關鍵因素。下一代定序（NGS）和聚合酶鏈反應（PCR）技術的日益複雜化，為乳癌的遺傳基礎提供了更深入的瞭解，並且可以檢測血液中微量的腫瘤 DNA。這些進展不僅提高了液體活檢的敏感性和特異性，而且拓寬了其潛在的應用，包括早期檢測、預後預測以及治療反應和抗藥性的監測。基因組技術的持續改進促進了液體活檢在臨床實踐中的廣泛應用。

對非侵入性手術的需求不斷增加

患者和醫療保健提供者對非侵入性診斷程序的偏好日益增加也是乳癌液體活檢市場發展的主要驅動力。傳統的組織活檢雖然有效，但具有侵入性並且常常引起不適和潛在的併發症。相較之下，液體活檢提供了一種微創的替代方法，只需抽血即可完成，從而減輕患者的壓力和風險。這種患者友善的方法對於監測腫瘤進展或治療反應所需的重複檢測特別有利，使得液體活檢成為持續疾病管理的一個有吸引力的選擇。

乳癌發生率上升

全球乳癌發生率的上升極大地刺激了對有效診斷和監測工具的需求，從而促進了液體活檢市場的發展。乳癌是世界上最常見的癌症之一，迫切需要先進的診斷技術，以便更早發現並改善患者的治療效果。液體活檢透過提供一種可以從血液樣本中檢測出早期癌症的工具來滿足這一需求，從而促進及時幹預和個人化治療計劃。全球範圍內乳癌發生率的不斷上升是推動液體活檢解決方案開發和應用的主要驅動力。

抑制因素

監管和報銷課題

儘管乳癌液體活檢市場具有潛力且正在成長，但它面臨著監管和報銷課題等方面的重大限制。由於液體活檢測試新穎而複雜，獲得 FDA 等機構監管批准的障礙很高。此外，缺乏使用和解釋液體活檢的標準化指南也增加了監管課題。在報銷方面，液體活檢的保險覆蓋範圍有限以及報銷政策不明確可能會阻礙醫療保健提供者採用這項技術。這些監管和報銷問題構成了巨大的障礙，阻礙了市場的成長和採用。

按生物標誌物細分的市場

乳癌液體切片市場按生物標記細分，例如循環腫瘤細胞（CTC）、無細胞 DNA（cfDNA）、外泌體和其他生物標記。其中，cfDNA因其在檢測和監測微小殘留疾病和治療抗藥性方面具有很高的臨床實用性，在收入方面處於領先地位。cfDNA 在臨床實踐中受到青睞，因為它可以快速、非侵入性地洞察腫瘤遺傳學。此外，由於定序技術的不斷進步和臨床應用的不斷增加，預計 cfDNA 在預測期內將呈現最高的複合年增長率 (CAGR)。然而，CTC 也發揮著重要作用，特別是在瞭解轉移過程方面，但由於其分離和分析相關的技術課題，它們僅佔市場的一小部分。外泌體越來越受歡迎，因為它們提供全面的分子訊息，可以深入瞭解腫瘤行為和治療反應。其他生物標誌物，包括蛋白質和代謝物，正在接受研究，並顯示出良好的前景，因為它們可以補充現有的生物標記物，從而實現更詳細的疾病分析和治療效果評估。

按產品/服務細分市場

乳癌液體活檢市場按產品/服務細分為試劑盒/試劑和服務。試劑盒和試劑佔據了主要收入，因為它們是液體活檢測試的基礎。該行業受益於與液體活檢相關的頻繁消費和定期購買，這些測試涉及患者治療過程中的多個測試階段。此外，旨在提高準確性和效率的試劑和試劑盒的不斷創新也支持了高收入。同時，服務業預計將以最高的複合年增長率成長。這種成長是由人們對包括測試交付、數據分析和可操作見解在內的綜合服務產品的日益增長的偏好所推動的。專業診斷服務的興起以及實驗室能力的擴大以適應先進的液體活檢技術，對這一領域的成長做出了重大貢獻。

地理趨勢

乳癌液體活檢市場呈現出動態的地理趨勢，由於先進的醫療保健基礎設施、對癌症篩檢的高度認識以及主要市場參與者的存在，北美目前在收入方面處於領先地位。然而，由於醫療支出增加、患者意識提高和醫療設施改善，亞太地區預計將在 2024 年至 2032 年期間呈現最高的複合年增長率 (CAGR)。中國、印度等國家乳癌發生率不斷上升，加上醫療技術投入不斷增加，推動了該地區乳癌的快速成長。由於強大的癌症診斷監管框架和高昂的醫療支出，歐洲也佔了相當大的市場佔有率。

競爭趨勢

乳癌液體切片市場正在迎來一些知名企業，例如 Datar Cancer Genetics、Epic Sciences、F. Hoffmann-La Roche、Genes2me、Illumina、Menarini Silicon Biosystems、Myriad Genetics、OncoDNA、QIAGEN、Sysmex、System Biosciences、Myriad Genetics、OncoDNA、QIAGEN、Sysmex、System Biosciences、Thermoist Fisher Scisciences。這些公司採取了各種策略來加強其市場地位並擴大其收入來源。2022年，這些公司實現了可觀的收入，反映了其市場主導地位和創新能力。預計這些公司在 2024-2032 年預測期內的策略將集中在技術創新、併購和地理擴張。例如，許多公司正在透過整合先進的基因組技術來增強其產品線，以提高液體活檢的準確性和可靠性。對於尋求全球擴張的公司來說，合作夥伴關係和協作也至關重要，尤其是進入亞太地區和拉丁美洲尚未開發的市場。此外，投資研發是這些公司的關鍵策略，旨在率先發現新的生物標記並提高現有液體活檢技術的靈敏度。這些策略努力符合全球整體市場擴張趨勢，預計將在未來幾年推動這些公司的持續成長和競爭優勢。

目錄

第1章 前言

  • 分析內容
    • 分析目的
    • 目標受眾
    • 主要產品
  • 市場細分
  • 分析方法
    • 第一階段：二次研究
    • 第二階段：初步調查
    • 第三階段：專家評審
    • 先決條件
    • 採取的方法

第 2 章 執行摘要

第 3 章 乳癌液體切片市場競爭分析

  • 主要廠商市場定位
  • 供應商採取的策略
  • 主要產業戰略

第 4 章 乳癌液體切片市場：宏觀分析與市場動態

  • 介紹
  • 全球乳癌液體活檢市場（價值，2022-2032 年）
  • 市場動態
    • 市場驅動力
    • 市場制約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析
  • 波特的五力模型
    • 供應商實力
    • 購買力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手之間的競爭
  • PESTEL 分析
    • 政局
    • 經濟情況
    • 技術情況
    • 法律狀況
    • 社會局勢

第 5 章 乳癌液體切片市場（依生物標記劃分） (2022-2032)

  • 市場概況
  • 成長/利潤分析：2023 年與 2032 年
  • 市場細分
    • 循環腫瘤細胞 (CTC)
    • 遊離 DNA（cfDNA）
    • 外泌體
    • 其他生物標誌物

第 6 章 乳癌液體切片市場（按產品和服務劃分） (2022-2032)

  • 市場概況
  • 成長/利潤分析：2023 年與 2032 年
  • 市場細分
    • 試劑盒/試劑
    • 服務

第 7 章 乳癌液體切片市場按樣本類型劃分（2022-2032 年）

  • 市場概況
  • 成長/利潤分析：2023 年與 2032 年
  • 市場細分
    • 血液
    • 尿
    • 其他類型的樣品

第 8 章 乳癌液體切片市場依最終用途劃分（2022-2032 年）

  • 市場概況
  • 成長/利潤分析：2023 年與 2032 年
  • 市場細分
    • 醫院
    • 癌症研究中心
    • 診斷中心
    • 學術研究所

第 9 章 北美乳癌液體切片市場（2022-2032）

  • 市場概況
  • 乳癌液體活檢市場（按生物標記） (2022-2032)
  • 乳癌液體活檢市場（按產品和服務劃分） (2022-2032)
  • 乳癌液體活檢市場（按樣本類型） (2022-2032)
  • 乳癌液體活檢市場按最終用途劃分（2022-2032 年）
  • 乳癌液體活檢市場（按地區） (2022-2032)
    • 北美
      • 美國
      • 加拿大
      • 其他北美

第 10 章 英國和歐盟乳癌液體活檢市場（2022-2032）

  • 市場概況
  • 乳癌液體活檢市場（按生物標記） (2022-2032)
  • 乳癌液體活檢市場（按產品和服務劃分） (2022-2032)
  • 乳癌液體活檢市場（按樣本類型） (2022-2032)
  • 乳癌液體活檢市場按最終用途劃分（2022-2032 年）
  • 乳癌液體活檢市場（按地區） (2022-2032)
    • 英國/歐盟國家
      • 英國
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 歐洲其他地區

第 11 章 亞太地區乳癌液體切片市場（2022-2032）

  • 市場概況
  • 乳癌液體活檢市場（按生物標記） (2022-2032)
  • 乳癌液體活檢市場（按產品和服務劃分） (2022-2032)
  • 乳癌液體活檢市場（按樣本類型） (2022-2032)
  • 乳癌液體活檢市場按最終用途劃分（2022-2032 年）
  • 乳癌液體活檢市場（按地區） (2022-2032)
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 亞太其他地區

第 12 章 拉丁美洲乳癌液體切片市場（2022-2032）

  • 市場概況
  • 乳癌液體活檢市場（按生物標記） (2022-2032)
  • 乳癌液體活檢市場（按產品和服務劃分） (2022-2032)
  • 乳癌液體活檢市場（按樣本類型） (2022-2032)
  • 乳癌液體活檢市場按最終用途劃分（2022-2032 年）
  • 乳癌液體活檢市場（按地區） (2022-2032)
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第 13 章 中東和非洲乳癌液體切片市場（2022-2032）

  • 市場概況
  • 乳癌液體活檢市場（按生物標記） (2022-2032)
  • 乳癌液體活檢市場（按產品和服務劃分） (2022-2032)
  • 乳癌液體活檢市場（按樣本類型） (2022-2032)
  • 乳癌液體活檢市場按最終用途劃分（2022-2032 年）
  • 乳癌液體活檢市場（按地區） (2022-2032)
    • 中東/非洲
      • 海灣合作委員會
      • 非洲
      • 其他中東/非洲地區

第14章 公司簡介

  • Datar Cancer Genetics
  • Epic Sciences
  • F. Hoffmann-La Roche
  • Genes2me
  • Illumina
  • Menarini Silicon Biosystems
  • Myriad Genetics
  • OncoDNA
  • QIAGEN
  • Sysmex
  • System Biosciences
  • Thermo Fisher Scientific
  • Twist Bioscience
  • 其他主要公司
Product Code: 140825-11-24

The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% during the forecast period of 2024 to 2032. Breast cancer liquid biopsy market is a rapidly evolving field that utilizes non-invasive liquid biopsies to detect and monitor breast cancer through blood samples. This method offers a significant advancement over traditional tissue biopsies, providing real-time insights into tumor dynamics and allowing for personalized treatment strategies. The technology's potential to revolutionize cancer detection and management has positioned it at the forefront of oncology research and clinical application.

Drivers

Advancements in Genomic Technologies

Technological advancements in genomic sequencing and analysis have been pivotal in driving the breast cancer liquid biopsy market. As next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have become more sophisticated, they offer deeper insights into the genetic basis of breast cancer, enabling the detection of minute quantities of tumor DNA in the bloodstream. These advancements have not only enhanced the sensitivity and specificity of liquid biopsies but have also broadened their potential applications, including early detection, prognosis, and monitoring of therapeutic efficacy and resistance. The continuous improvements in genomic technologies underscore their role in the growing adoption of liquid biopsies in clinical settings.

Growing Demand for Non-Invasive Procedures

The increasing preference for non-invasive diagnostic procedures among both patients and healthcare providers is another significant driver for the breast cancer liquid biopsy market. Traditional tissue biopsies, while effective, are invasive and often lead to discomfort and potential complications. In contrast, liquid biopsies offer a minimally invasive alternative that can be performed with a simple blood draw, reducing patient stress and risk. This patient-friendly approach is particularly advantageous for repeated testing required in monitoring tumor progression and response to treatment, making liquid biopsies an attractive option for continuous disease management.

Rising Prevalence of Breast Cancer

The rising global prevalence of breast cancer significantly fuels the demand for effective diagnostic and monitoring tools, boosting the liquid biopsy market. With breast cancer being one of the most common cancers worldwide, there is an urgent need for advancements in diagnostic techniques that can lead to earlier detection and improved patient outcomes. Liquid biopsies meet this need by providing a tool that can detect cancer at its earliest stages from a blood sample, facilitating timely intervention and personalized treatment plans. The increasing incidence of breast cancer globally is a compelling driver for the development and adoption of liquid biopsy solutions.

Restraint

Regulatory and Reimbursement Challenges

Despite the potential and growth of the breast cancer liquid biopsy market, it faces significant restraints with regulatory and reimbursement challenges. The novelty and complexity of liquid biopsy tests pose hurdles in gaining regulatory approvals from bodies like the FDA, as these agencies require extensive validation of the tests' clinical utility and accuracy before they can be broadly implemented. Furthermore, the lack of standardized guidelines for the use and interpretation of liquid biopsies adds to the regulatory challenges. On the reimbursement front, insufficient coverage and unclear reimbursement policies for liquid biopsies can deter healthcare providers from adopting this technology, as the financial costs of these advanced tests are often higher than traditional methods. These regulatory and reimbursement issues are substantial obstacles that slow the market's growth and widespread adoption.

Market Segmentation by Biomarkers

The breast cancer liquid biopsy market is segmented by biomarkers, including Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Exosomes, and Other Biomarkers. Among these, cfDNA leads in revenue generation due to its high clinical utility in detecting and monitoring minimal residual disease and treatment resistance. Its ability to provide rapid, non-invasive insights into tumor genetics makes cfDNA a preferred choice in clinical settings. Furthermore, cfDNA is projected to exhibit the highest Compound Annual Growth Rate (CAGR) over the forecast period, driven by continuous advancements in sequencing technologies and increasing clinical adoption. On the other hand, CTCs also play a crucial role, particularly in understanding metastatic processes, though they capture a smaller portion of the market due to the technical challenges associated with their isolation and analysis. Exosomes are gaining traction as they provide comprehensive molecular information that potentially offers insights into tumor behavior and response to therapy. The segment of Other Biomarkers, which includes proteins and metabolites, shows promise due to ongoing research and potential to complement existing biomarkers for a more detailed disease profiling and treatment efficacy evaluation.

Market Segmentation by Products & Services

In the breast cancer liquid biopsy market, segmentation by Products & Services includes Kits & Reagents and Services. Kits & Reagents dominate in terms of revenue, as they are the foundational components used in liquid biopsy tests. This segment benefits from the frequent consumption and recurring purchases associated with liquid biopsy procedures, which involve multiple stages of testing over a patient's treatment course. Additionally, the ongoing innovation in reagents and kits, aimed at enhancing accuracy and efficiency, supports their high revenue generation. Meanwhile, Services are expected to witness the highest CAGR. This growth is fueled by the increasing preference for comprehensive service offerings that include test execution, data analysis, and actionable insights, which are highly valued in clinical settings for making informed treatment decisions. The rise in specialized diagnostic services and the expansion of laboratory capabilities to accommodate advanced liquid biopsy technologies contribute significantly to the growth of this segment.

Geographic Trends

The breast cancer liquid biopsy market demonstrates dynamic geographic trends, with North America currently leading in terms of revenue due to its advanced healthcare infrastructure, high awareness about cancer screenings, and the presence of key market players. However, Asia-Pacific is expected to exhibit the highest Compound Annual Growth Rate (CAGR) from 2024 to 2032, driven by rising healthcare expenditures, increasing patient awareness, and improving healthcare facilities. The growing prevalence of breast cancer in countries like China and India, coupled with increasing investments in healthcare technologies, fuels the rapid growth in this region. Europe also maintains a significant share in the market, supported by its strong regulatory frameworks for cancer diagnostics and substantial healthcare spending.

Competitive Trends

In terms of competitive trends, the market sees robust participation from companies like Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, QIAGEN, Sysmex, System Biosciences, Thermo Fisher Scientific, and Twist Bioscience. These entities have leveraged various strategies to solidify their market positions and expand their revenue streams. In 2022, these companies reported substantial revenues, reflecting their dominance and innovative capabilities within the market. Their strategies for the forecast period of 2024 to 2032 are expected to focus on technological innovations, mergers and acquisitions, and geographic expansion. For instance, many of these firms are enhancing their product lines with integrations of advanced genomic technologies to increase the accuracy and reliability of liquid biopsies. Partnerships and collaborations are also crucial as companies aim to expand their global footprints, particularly in untapped markets within Asia-Pacific and Latin America. Moreover, investment in research and development is a key strategy for these companies, aiming to lead in the discovery of novel biomarkers and improve the sensitivity of existing liquid biopsy techniques. These strategic efforts are anticipated to drive the continued growth and competitive edge of these companies in the upcoming years, aligning with the overall expansion trends seen across the global market.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Breast Cancer Liquid Biopsy market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Breast Cancer Liquid Biopsy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
  • Biomarkers
    • Circulating tumor cells (CTCs)
    • Cell-free DNA (cfDNA)
    • Exosomes
    • Other biomarkers
  • Products & Services
    • Kits & reagents
    • Services
  • Sample Type
    • Blood
    • Urine
    • Other sample types
  • End Use
    • Hospitals
    • Cancer research centers
    • Diagnostic centers
    • Academic and research institutes
  • Region Segment (2022-2032; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Breast Cancer Liquid Biopsy market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Breast Cancer Liquid Biopsy market?
  • Which is the largest regional market for Breast Cancer Liquid Biopsy market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Breast Cancer Liquid Biopsy market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Breast Cancer Liquid Biopsy market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Breast Cancer Liquid Biopsy Market
  • 2.2. Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 (US$ Million)
  • 2.3. Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 (US$ Million)
  • 2.4. Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 (US$ Million)
  • 2.5. Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 (US$ Million)
  • 2.6. Global Breast Cancer Liquid Biopsy Market, By Geography, 2023 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2023

3. Breast Cancer Liquid Biopsy Market: Competitive Analysis

  • 3.1. Market Positioning of Key Breast Cancer Liquid Biopsy Market Vendors
  • 3.2. Strategies Adopted by Breast Cancer Liquid Biopsy Market Vendors
  • 3.3. Key Industry Strategies

4. Breast Cancer Liquid Biopsy Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Breast Cancer Liquid Biopsy Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Market Segmentation
    • 5.3.1. Circulating tumor cells (CTCs)
    • 5.3.2. Cell-free DNA (cfDNA)
    • 5.3.3. Exosomes
    • 5.3.4. Other biomarkers

6. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Market Segmentation
    • 6.3.1. Kits & reagents
    • 6.3.2. Services

7. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 7.3. Market Segmentation
    • 7.3.1. Blood
    • 7.3.2. Urine
    • 7.3.3. Other sample types

8. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 8.3. Market Segmentation
    • 8.3.1. Hospitals
    • 8.3.2. Cancer research centers
    • 8.3.3. Diagnostic centers
    • 8.3.4. Academic and research institutes

9. North America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 9.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 9.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 9.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 9.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 9.6.1.North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 9.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 9.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 9.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 9.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 9.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 9.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 9.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 9.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 9.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

10. UK and European Union Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 10.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 10.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 10.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 10.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 10.6.1.UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

11. Asia Pacific Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 11.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 11.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 11.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 11.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 11.6.1.Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

12. Latin America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 12.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 12.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 12.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 12.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 12.6.1.Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 12.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 12.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 12.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 12.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 12.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 12.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 12.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 12.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 12.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

13. Middle East and Africa Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 13.1. Market Overview
  • 13.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 13.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 13.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 13.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 13.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 13.6.1.Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 13.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 13.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 13.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 13.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 13.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 13.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 13.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 13.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 13.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

14. Company Profile

  • 14.1. Datar Cancer Genetics
    • 14.1.1. Company Overview
    • 14.1.2. Financial Performance
    • 14.1.3. Product Portfolio
    • 14.1.4. Strategic Initiatives
  • 14.2. Epic Sciences
    • 14.2.1. Company Overview
    • 14.2.2. Financial Performance
    • 14.2.3. Product Portfolio
    • 14.2.4. Strategic Initiatives
  • 14.3. F. Hoffmann-La Roche
    • 14.3.1. Company Overview
    • 14.3.2. Financial Performance
    • 14.3.3. Product Portfolio
    • 14.3.4. Strategic Initiatives
  • 14.4. Genes2me
    • 14.4.1. Company Overview
    • 14.4.2. Financial Performance
    • 14.4.3. Product Portfolio
    • 14.4.4. Strategic Initiatives
  • 14.5. Illumina
    • 14.5.1. Company Overview
    • 14.5.2. Financial Performance
    • 14.5.3. Product Portfolio
    • 14.5.4. Strategic Initiatives
  • 14.6. Menarini Silicon Biosystems
    • 14.6.1. Company Overview
    • 14.6.2. Financial Performance
    • 14.6.3. Product Portfolio
    • 14.6.4. Strategic Initiatives
  • 14.7. Myriad Genetics
    • 14.7.1. Company Overview
    • 14.7.2. Financial Performance
    • 14.7.3. Product Portfolio
    • 14.7.4. Strategic Initiatives
  • 14.8. OncoDNA
    • 14.8.1. Company Overview
    • 14.8.2. Financial Performance
    • 14.8.3. Product Portfolio
    • 14.8.4. Strategic Initiatives
  • 14.9. QIAGEN
    • 14.9.1. Company Overview
    • 14.9.2. Financial Performance
    • 14.9.3. Product Portfolio
    • 14.9.4. Strategic Initiatives
  • 14.10. Sysmex
    • 14.10.1. Company Overview
    • 14.10.2. Financial Performance
    • 14.10.3. Product Portfolio
    • 14.10.4. Strategic Initiatives
  • 14.11. System Biosciences
    • 14.11.1. Company Overview
    • 14.11.2. Financial Performance
    • 14.11.3. Product Portfolio
    • 14.11.4. Strategic Initiatives
  • 14.12. Thermo Fisher Scientific
    • 14.12.1. Company Overview
    • 14.12.2. Financial Performance
    • 14.12.3. Product Portfolio
    • 14.12.4. Strategic Initiatives
  • 14.13. Twist Bioscience
    • 14.13.1. Company Overview
    • 14.13.2. Financial Performance
    • 14.13.3. Product Portfolio
    • 14.13.4. Strategic Initiatives
  • 14.14. Other Notable Players
    • 14.14.1. Company Overview
    • 14.14.2. Financial Performance
    • 14.14.3. Product Portfolio
    • 14.14.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 2 Global Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 3 Global Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 4 Global Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 5 North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 6 North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 7 North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 8 North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 9 U.S. Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 10 U.S. Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 11 U.S. Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 12 U.S. Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 13 Canada Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 14 Canada Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 15 Canada Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 16 Canada Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 17 Rest of North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 18 Rest of North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 19 Rest of North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 20 Rest of North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 21 UK and European Union Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 22 UK and European Union Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 23 UK and European Union Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 24 UK and European Union Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 25 UK Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 26 UK Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 27 UK Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 28 UK Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 29 Germany Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 30 Germany Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 31 Germany Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 32 Germany Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 33 Spain Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 34 Spain Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 35 Spain Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 36 Spain Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 37 Italy Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 38 Italy Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 39 Italy Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 40 Italy Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 41 France Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 42 France Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 43 France Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 44 France Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 45 Rest of Europe Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 46 Rest of Europe Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 47 Rest of Europe Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 48 Rest of Europe Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 49 Asia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 50 Asia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 51 Asia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 52 Asia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 53 China Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 54 China Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 55 China Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 56 China Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 57 Japan Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 58 Japan Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 59 Japan Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 60 Japan Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 61 India Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 62 India Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 63 India Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 64 India Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 65 Australia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 66 Australia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 67 Australia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 68 Australia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 69 South Korea Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 70 South Korea Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 71 South Korea Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 72 South Korea Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 73 Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 74 Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 75 Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 76 Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 77 Brazil Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 78 Brazil Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 79 Brazil Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 80 Brazil Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 81 Mexico Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 82 Mexico Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 83 Mexico Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 84 Mexico Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 85 Rest of Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 86 Rest of Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 87 Rest of Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 88 Rest of Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 89 Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 90 Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 91 Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 92 Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 93 GCC Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 94 GCC Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 95 GCC Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 96 GCC Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 97 Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 98 Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 99 Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 100 Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 101 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 102 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 103 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 104 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Breast Cancer Liquid Biopsy Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Breast Cancer Liquid Biopsy Market: Quality Assurance
  • FIG. 5 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023
  • FIG. 6 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023
  • FIG. 7 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023
  • FIG. 8 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023
  • FIG. 9 Global Breast Cancer Liquid Biopsy Market, By Geography, 2023
  • FIG. 10 Market Geographical Opportunity Matrix - Global Breast Cancer Liquid Biopsy Market, 2023
  • FIG. 11Market Positioning of Key Breast Cancer Liquid Biopsy Market Players, 2023
  • FIG. 12Global Breast Cancer Liquid Biopsy Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
  • FIG. 13 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 Vs 2032, %
  • FIG. 14 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 Vs 2032, %
  • FIG. 15 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 Vs 2032, %
  • FIG. 16 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 Vs 2032, %
  • FIG. 17 U.S. Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 18 Canada Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 19 Rest of North America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 20 UK Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 21 Germany Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 22 Spain Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 23 Italy Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 24 France Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 25 Rest of Europe Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 26 China Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 27 Japan Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 28 India Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 29 Australia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 30 South Korea Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 31 Rest of Asia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 32 Brazil Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 33 Mexico Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 34 Rest of Latin America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 35 GCC Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 36 Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 37 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032